Advertisement

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME

About the Journal
Editorial Board & Staff

About JACC CME
Hardware/Software Requirements
Contact Us
Policy on Privacy and Confidentiality
Copyright Information

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions

Click here for more guidelines.
2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
ACC 2009 Advocacy Position Statement: Principles for Comparative Effectiveness Research
ACC 2009 Survey Results and Recommendations: Addressing the Cardiology Workforce Crisis
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:2312-2317, doi:10.1016/j.jacc.2007.01.094 (Published online 1 June 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Cardiosource Expert Opinion
Right arrow All Versions of this Article:
j.jacc.2007.01.094v1
49/24/2312    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (134)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buonamici, P.
Right arrow Articles by Antoniucci, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Buonamici, P.
Right arrow Articles by Antoniucci, D.
Related Collections
Right arrowRelated Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis

Piergiovanni Buonamici, MD, Rossella Marcucci, MD, Angela Migliorini, MD, Gian Franco Gensini, MD, Alberto Santini, MD, Rita Paniccia, MD, Guia Moschi, MD, Anna Maria Gori, MD, Rosanna Abbate, MD and David Antoniucci, MD*

Department of Cardiology, Careggi Hospital, Florence, Italy.

Manuscript received January 2, 2007; revised manuscript received January 26, 2007, accepted January 28, 2007.

* Reprint requests and correspondence: Dr. David Antoniucci, Division of Cardiology, Careggi Hospital, Viale Pieraccini, I-50134, Florence, Italy. (Email: david.antoniucci{at}virgilio.it).

Objectives: We sought to determine whether nonresponsiveness to clopidogrel as revealed by high in vitro post-treatment platelet reactivity is predictive of drug-eluting stent (DES) thrombosis.

Background: No data exist about the impact of nonresponsiveness to clopidogrel on the risk of DES thrombosis.

Methods: We conducted a prospective observational cohort study from July 2005 to August 2006 in an academic hospital. A total of 804 patients who had successful sirolimus- or paclitaxel-eluting stent implantation were assessed for post-treatment platelet reactivity after a loading dose of 600 mg of clopidogrel. Patients with platelet aggregation by 10 µmol adenosine 5'-diphosphate ≥70% were defined as nonresponders. All patients received chronic dual antiplatelet treatment (aspirin 325 mg and clopidogrel 75 mg daily) for 6 months. The primary end point was the incidence of definite/probable early, subacute, and late stent thrombosis at 6-month follow-up.

Results: The incidence of 6-month definite/probable stent thrombosis was 3.1%. All stent thromboses were subacute or late. Of 804 patients, 105 (13%) were not responsive to clopidogrel. The incidence of stent thrombosis was 8.6% in nonresponders and 2.3% in responders (p < 0.001). By multivariate analysis, the predictors of stent thrombosis were as follows: nonresponsiveness to clopidogrel (hazard ratio [HR] 3.08, 95% confidence interval [CI] 1.32 to 7.16; p = 0.009), left ventricular ejection fraction (HR 0.95, 95% CI 0.92 to 0.98; p = 0.001), total stent length (HR 1.01, 95% CI 1.00 to 1.02; p = 0.010), and ST-segment elevation acute myocardial infarction (HR 2.41, 95% CI 1.04 to 5.63; p = 0.041).

Conclusions: Nonresponsiveness to clopidogrel is a strong independent predictor of stent thrombosis in patients receiving sirolimus- or paclitaxel-eluting stents.

Abbreviations and Acronyms
  ADP = adenosine 5'-diphosphate
  AMI = acute myocardial infarction
  CI = confidence interval
  DES = drug-eluting stent(s)
  HR = hazard ratio
  LVEF = left ventricular ejection fraction


Related Article

Unraveling Questions Surrounding Clopidogrel Resistance and Stent Thrombosis: One Less Snag
David J. Moliterno and Charles L. Campbell
J. Am. Coll. Cardiol. 2007 49: 2318-2319. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
G. Dangas, R. Mehran, G. Guagliumi, A. Caixeta, B. Witzenbichler, J. Aoki, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, et al.
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1438 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. I. Simon and S. A. Parikh
Hunting for the "Sweet Spot" in P2Y12 Receptor Blockade
J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1447 - 1449.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
T. Geisler, C. Zurn, R. Simonenko, M. Rapin, H. Kraibooj, A. Kilias, B. Bigalke, K. Stellos, M. Schwab, A. E. May, et al.
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions
Eur. Heart J., October 6, 2009; (2009) ehp402v1.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
Z J Wang, Y J Zhou, Y Y Liu, M Yu, D M Shi, Y X Zhao, Y H Guo, W J Cheng, B Nie, H L Ge, et al.
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents
Heart, October 1, 2009; 95(19): 1587 - 1592.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, O. Brissy, P.-E. Morange, M.-C. Alessi, and J.-L. Bonnet
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
J. Am. Coll. Cardiol., September 22, 2009; 54(13): 1149 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano
Antithrombotics in acute coronary syndromes.
J. Am. Coll. Cardiol., September 8, 2009; 54(11): 969 - 984.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. R. Shuldiner, J. R. O'Connell, K. P. Bliden, A. Gandhi, K. Ryan, R. B. Horenstein, C. M. Damcott, R. Pakyz, U. S. Tantry, Q. Gibson, et al.
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
JAMA, August 26, 2009; 302(8): 849 - 857.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. Verstuyft, T. Simon, and R. B. Kim
Personalized medicine and antiplatelet therapy: ready for prime time?
Eur. Heart J., August 2, 2009; 30(16): 1943 - 1963.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
C. S. Ernest II, M. A. Heathman, and R. E. Wrishko
Prediction of Prasugrel Active Metabolite Concentrations From 2 Downstream Inactive Metabolite Concentrations Using Multilinear Regression Analysis
J. Clin. Pharmacol., August 1, 2009; 49(8): 973 - 983.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
L Bonello, A De Labriolle, M Scheinowitz, G Lemesle, P Roy, D H Steinberg, T L Pinto Slottow, R Pakala, A D Pichard, P Barragan, et al.
Emergence of the concept of platelet reactivity monitoring of response to thienopyridines
Heart, August 1, 2009; 95(15): 1214 - 1219.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
J. P. Chen, D. Hou, L. Pendyala, J. A. Goudevenos, and N. G. Kounis
Drug-Eluting Stent Thrombosis: The Kounis Hypersensitivity-Associated Acute Coronary Syndrome Revisited
J. Am. Coll. Cardiol. Intv., July 1, 2009; 2(7): 583 - 593.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, D. J. Angiolillo, M. Sabate, M. Hamon, A. Repetto, et al.
Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Study
Circulation, June 30, 2009; 119(25): 3215 - 3222.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
R. Paniccia, E. Antonucci, N. Maggini, E. Romano, A. M. Gori, R. Marcucci, D. Prisco, and R. Abbate
Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy
Am J Clin Pathol, June 1, 2009; 131(6): 834 - 842.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
A. Prasad and D. R Holmes
Update on dual antiplatelet therapy for percutaneous coronary intervention
Heart, June 1, 2009; 95(11): 861 - 865.
[Full Text] [PDF]

Home page
 CirculationHome page
M. J. Price
Bedside Evaluation of Thienopyridine Antiplatelet Therapy
Circulation, May 19, 2009; 119(19): 2625 - 2632.
[Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
D. A Gorog, S. Saraf, and V. Markides
Coronary thrombosis: In vivo, ex vivo and in vitro
BMJ Case Reports, April 14, 2009; 2009(apr07_2): bcr0920080983 - bcr0920080983.
[Abstract] [Full Text]

Home page
 Eur Heart JHome page
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J., April 2, 2009; 30(8): 916 - 922.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.
J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1101 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati, and N. von Beckerath
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
J. Am. Coll. Cardiol., March 10, 2009; 53(10): 849 - 856.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Mahla, M. J. Antonino, U. S. Tantry, and P. A. Gurbel
Point-of-care platelet function analysis ready for prime time?
J. Am. Coll. Cardiol., March 10, 2009; 53(10): 857 - 859.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. A. Gurbel, K. P. Bliden, J. F. Saucedo, T. A. Suarez, J. DiChiara, M. J. Antonino, E. Mahla, A. Singla, W. R. Herzog, A. K. Bassi, et al.
Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction Results of the CLEAR PLATELETS-2 (Clopidogrel With Eptifibatide to Arrest the Reactivity of Platelets) Study.
J. Am. Coll. Cardiol., February 24, 2009; 53(8): 648 - 657.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, et al.
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
Eur. Heart J., February 2, 2009; 30(4): 426 - 435.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
J. P. Chen, L. V. Crisco, R. Jabara, and S. B. King III
Late Angiographic Stent Thrombosis: The LAST Straw for Drug-Eluting Stents?
Angiology, January 1, 2009; 59(6): 667 - 675.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
F. Burzotta, A. Parma, C. Pristipino, A. Manzoli, F. Belloni, G. Sardella, S. Rigattieri, A. Danesi, P. Mazzarotto, F. Summaria, et al.
Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study
Eur. Heart J., December 2, 2008; 29(24): 3011 - 3021.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
L. Ang and E. Mahmud
Monitoring oral antiplatelet therapy: is it justified?
Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 485 - 496.
[Abstract] [PDF]

Home page
 Circ Cardiovasc IntervHome page
A. K. Chhatriwalla and D. L. Bhatt
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely
Circ Cardiovasc Interv, December 1, 2008; 1(3): 217 - 225.
[Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
A. Colombo and R. T. Gerber
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Circ Cardiovasc Interv, December 1, 2008; 1(3): 226 - 232.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
N. S. Kleiman
Searching for the Ceiling: New Reflections on the Disposition and Metabolism of Clopidogrel
J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 628 - 630.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
T. Cuisset, C. Frere, J. Quilici, P.-E. Morange, J.-P. Mouret, L. Bali, P.-J. Moro, M. Lambert, M.-C. Alessi, and J. L. Bonnet
Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders: A Prospective, Randomized Study
J. Am. Coll. Cardiol. Intv., December 1, 2008; 1(6): 649 - 653.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
G. De Luca
Adjunctive antithrombotic therapy during primary percutaneous coronary intervention
Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. S. Kleiman
Clopidogrel and Calcium-Channel Antagonists: Another Drug-Drug Interaction for the Ever-Wary Clinician?
J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1564 - 1566.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
S. A. Murphy, E. M. Antman, S. D. Wiviott, G. Weerakkody, G. Morocutti, K. Huber, J. Lopez-Sendon, C. H. McCabe, E. Braunwald, and for the TRITON-TIMI 38 Investigators
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
Eur. Heart J., October 2, 2008; 29(20): 2473 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. Ang, V. Palakodeti, A. Khalid, S. Tsimikas, Z. Idrees, P. Tran, P. Clopton, N. Zafar, G. Bromberg-Marin, S. Keramati, et al.
Elevated Plasma Fibrinogen and Diabetes Mellitus Are Associated With Lower Inhibition of Platelet Reactivity With Clopidogrel
J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1052 - 1059.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J.-P. Collet, J. Silvain, A. Landivier, M.-L. Tanguy, G. Cayla, A. Bellemain, N. Vignolles, S. Gallier, F. Beygui, A. Pena, et al.
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study
Circulation, September 16, 2008; 118(12): 1225 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Chieffo, S.-J. Park, E. Meliga, I. Sheiban, M. S. Lee, A. Latib, Y.-H. Kim, M. Valgimigli, D. Sillano, V. Magni, et al.
Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry
Eur. Heart J., September 1, 2008; 29(17): 2108 - 2115.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Y.-H. Jeong, I.-S. Kim, B.-R. Choi, C. H. Kwak, and J.-Y. Hwang
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay
Eur. Heart J., September 1, 2008; 29(17): 2186 - 2187.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Paniccia, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate, et al.
Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 734 - 739.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Trenk and F.-J. Neumann
Aspirin Resistance: An Underestimated Risk in Patients With Drug-Eluting Stents?
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 740 - 742.
[Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
D. R. Holmes Jr and D. O. Williams
Catheter-Based Treatment of Coronary Artery Disease: Past, Present, and Future
Circ Cardiovasc Interv, August 1, 2008; 1(1): 60 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. J. Price
New antiplatelet therapies in development
Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S11 - S15.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2355 - 2369.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
D. Sibbing, G. Busch, S. Braun, S. Jawansky, A. Schomig, A. Kastrati, I. Ott, and N. von Beckerath
Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
Eur. Heart J., June 2, 2008; 29(12): 1504 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Trenk, W. Hochholzer, M. F. Fromm, L.-E. Chialda, A. Pahl, C. M. Valina, C. Stratz, P. Schmiebusch, H.-P. Bestehorn, H. J. Buttner, et al.
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1925 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. A. Cairns and J. Eikelboom
Clopidogrel Resistance: More Grist for the Mill
J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1935 - 1937.
[Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
L. Wallentin
Dual antiplatelet therapy in the drug-eluting stent era
Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D38 - D44.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. J. Price, S. Endemann, R. R. Gollapudi, R. Valencia, C. T. Stinis, J. P. Levisay, A. Ernst, N. S. Sawhney, R. A. Schatz, and P. S. Teirstein
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Eur. Heart J., April 2, 2008; 29(8): 992 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. L. L'Allier, G. Ducrocq, N. Pranno, S. Noble, R. Ibrahim, J. C. Gregoire, F. Azzari, A. Nozza, C. Berry, S. Doucet, et al.
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1066 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. D. Michelson
P2Y12 Antagonism: Promises and Challenges
Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): s33 - s38.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512.
[Full Text] [PDF]

Home page
 CirculationHome page
S. D. Wiviott, D. Trenk, A. L. Frelinger, M. O'Donoghue, F.-J. Neumann, A. D. Michelson, D. J. Angiolillo, H. Hod, G. Montalescot, D. L. Miller, et al.
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 Trial
Circulation, December 18, 2007; 116(25): 2923 - 2932.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. D. Wiviott, E. Braunwald, C. H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.-J. Neumann, D. Ardissino, S. De Servi, S. A. Murphy, et al.
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
N. Engl. J. Med., November 15, 2007; 357(20): 2001 - 2015.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834.
[Abstract] [Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Nonresponsiveness to Clopidogrel and Subsequent Drug-Eluting Stent Thrombosis
Journal Watch Cardiology, July 11, 2007; 2007(711): 3 - 3.
[Full Text]

Home page
 J Am Coll CardiolHome page
D. J. Moliterno and C. L. Campbell
Unraveling Questions Surrounding Clopidogrel Resistance and Stent Thrombosis: One Less Snag
J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2318 - 2319.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
D. J. Fitzgerald and A. Maree
Aspirin and Clopidogrel Resistance
Hematology, January 1, 2007; 2007(1): 114 - 120.
[Abstract] [Full Text] [PDF]


 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement